Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), By Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostate Cancer, and Others), By End User (Hospitals, Cancer Research Centers, and Others), and By Region - Trends, Analysis and Forecast till 2034

Cancer Immunotherapy Market Size was valued at USD 158.5 Billion in 2024 and is expected to reach USD 530.2 Billion by 2034, growing at a CAGR of 14.2%

Cancer immunotherapy represents a new and bright approach to cancer treatment, whereby one's immune system is manipulated to battle malignant cells. This new approach for treating cancers works by stimulating or enhancing natural defense mechanisms of the immune system itself to either engender or enhance its ability to recognize and attack the tumor cells. Whereas the traditional modes of treatment for cancer, such as chemotherapy or radiation, hit hard at the cancer cells and take their toll on healthy tissues, too, immunotherapy tends to be based on the enhancement of the body's innate ability to fight the disease. There are several ways in which cancer immunotherapy works. Checkpoint inhibitors are medications that shut off specific proteins that tone down the immune cells' activity to struggle against cancer cells, thereby "removing the brakes" of the immune system. With CAR T-cell therapy, a patient's T-cells are genetically modified to enhance their ability to recognize and target tumor cells. Cancer vaccines stimulate a person's immune system to recognize specific antigens on cancer cells. Monoclonal antibodies bind to specific targets on cancer cells, marking them for destruction by the immune system. Cytokines are small proteins that often help modulate immune responses and can be used to enhance the overall immune response against cancer.

It has tremendously succeeded in treating melanoma, lung, bladder, and blood cancers. In some instances, it brought long-term remissions—cures, really—to patients otherwise out of options. But thousands more should know that not all treatments by immunotherapy work with patients or even against all types of cancer. Researchers are still working to understand why some do much better than others. One of the most important advantages of immunotherapy is its long-term effectiveness. This is because once the immune system is trained to recognize and attack cancer cells, it will do this over a long time, thus preventing the reoccurrence of cancer. Moreover, it often results in fewer side effects as compared to the traditional treatment of cancer, though sometimes it causes some unique immune-related adverse events, which require careful management.

Research in cancer immunotherapy is progressing, and efforts are now directed toward combination therapies, personalized approaches based on the genetic profile of individual patients, and ways in which the benefits of immunotherapy might be extended to more types of cancer. It is foreseen that the development of cancer immunotherapy will finally define one of the most significant paradigm changes in oncology, offering new hope to patients and leading the way toward more focused, effective, and less toxic cancer treatments.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Key Drivers of Target Market:

Increasing Cancer Prevalence:

• The total burden of cancer is rising across the globe, and more patients are diagnosed with various forms of it. This has resulted in a vast market for immunotherapy treatment. Because the incidence of cancers is continually increasing, the demand for its therapies, such as immunotherapy, is also rising.

Rising Efficacy of Immunotherapy:

• Research innovations in this area have led to the creation of highly effective treatments, where cells causing cancer can be targeted for elimination by immunotherapy. As a result, a tremendous amount of interest and investment in treatment given challenging cancers, respectively, has attracted to this sphere of therapy. The continual results it has portrayed from its clinical trials mean that there is the potential for further growth in the adoption of immunotherapy.

Growing Research and Development:

• Investments in cancer immunotherapy research are essential for new treatment approaches. An increasing understanding of the immune system and its interaction with cancer has found novel targets and therapeutic strategies. This pipeline of immunotherapies is thus growing in response to the growing research.

Restrains:

High Cost of Treatment:

• One major drawback of this therapy, however, is its high cost, which limits its wide adoption. Immunotherapy is costly, as most of these treatments are complex and demand expert care. Because of the cost aspect, very rare grounds are covered, especially patient access, in areas where health coverage is quite low.

Opportunities:

Expanding Treatment Indications:

• The expansion of cancer immunotherapy to other areas of cancer is also seen as an important opportunity. While there has been massive success in immunotherapy for some types of cancer, there is huge scope for treatments for other solid tumors and hematological malignancies. The identification of new immune targets and the development of innovative therapies could further expand the market.

Combination Therapies:

• Potentiating immunotherapy for better clinical response with a combination of other treatment modalities, such as chemotherapy, radiation, or targeted therapies, would be a promising approach. Combining these approaches optimally would yield synergistic effects, improving patient outcomes and outsmarting acquired treatment resistances. Such a trial-combining strategy for improved therapeutic opportunities has a big scope for market interest.

The market is segmented based on Product Type, Cancer Type, End-User, and Region.

Product Type Insights:

• Monoclonal Antibodies: These are just laboratory-designed molecules that mimic the actions of the immune system against such harmful pathogens as cancer cells. The antibodies bind with specific proteins on the surface of a cancer cell, stopping or slowing its growth and other signaling pathways or inducing the immune system to destroy them. They are among the most applied forms of cancer immunotherapy and include such treatments as Rituxan and Herceptin. The monoclonal antibodies can also be conjugated with toxins, radioactive substances, or other drugs that kill cancer cells.
• Immunomodulators: Immunomodulators are medications that change the response of the immune system to the tumor. They either stimulate or suppress the immune system so that the body can fight cancer more effectively. One widespread application of immunomodulators such as thalidomide, lenalidomide, and pomalidomide is in the treatment of multiple myeloma. These medicines act by changing the microenvironment of the tumor cells, enhancing immune responses, and inhibiting angiogenesis—that is, the process by which new blood vessels supplying the tumors develop.
• Checkpoint Inhibitors: This class of drugs works by inhibiting the activity of proteins that cancer cells utilize to evade the immune system. It does this by releasing the inhibition on these checkpoints, such as PD-1, PD-L1, or CTLA-4, and allows the immune system to finally detect and kill cancer cells. They include nivolumab, pembrolizumab, and ipilimumab, which have been very instrumental in treating cancers like melanoma and lung cancer.
• Adoptive Cell Therapy: ACT involves harvesting a patient's immune cells and turning them against cancer. The most prominent form of ACT is CAR-T cell therapy, involving gene editing of T cells for better identification and action against cancer cells. It has been broadly successful, especially in treating certain blood cancers like leukemia and lymphoma. ACT represents one of the personalized approaches to treatment with high specificity and potential durability.
• Others: Others include cancer vaccines, cytokines, and oncolytic virus therapy. Cancer vaccines are the type of immunotherapies that would prevent or even treat cancer by enhancing the capacities of the immune system to recognize and destroy these cancer cells. Cytokines are any immunoregulatory molecules that modulate the biological response and increase the body's natural immune response. Oncolytic viruses are genetically re-engineered to infect and kill only cancer cells.

Cancer Type Insights:

• Lung Cancer: Lung cancer is one of the most common cancers being treated with immunotherapy. Checkpoint inhibitors, specifically PD-1/PD-L1 inhibitors, have been incorporated into the standard armamentarium for advanced NSCLC. These therapies are associated with superior survival compared with chemotherapy.
• Colorectal Cancer: In colorectal cancer, immunotherapy is mainly given in those patients with a high level of microsatellite instability tumors. Such tumors have many mutations, making them more 'visible' to the immune system. Checkpoint inhibitors such as pembrolizumab are approved for MSI-H colorectal cancer treatment.
• Melanoma: Immunotherapy, notably with checkpoint inhibitors, has greatly benefited melanoma, a type of skin cancer. Therapies such as nivolumab and pembrolizumab have improved the clinical outcomes of patients suffering from advanced melanoma and often provided long-term remission.
• Breast Cancer: Historically, this was less responsive to immunotherapy than many other cancers; however, checkpoint inhibitors have shown some benefits against certain types of breast cancer, especially triple-negative breast cancer. The immunotherapy is combined with chemotherapy to improve the general response.
• Head & Neck Cancer: Immunotherapy has become the most crucial treatment for patients suffering from recurrent or metastatic head and neck squamous cell carcinoma. Inhibitors are used after the failure of conventional therapies, providing a new life to patients with very narrow options.
• Prostate Cancer: Most prostate cancer immunotherapy has focused on therapeutic vaccines and checkpoint inhibitors. While results have been more modest compared with other cancers, ongoing research focuses on how to optimize these therapies for better outcomes in patients with prostate cancer.
• Others: Others include the remainder, most notably bladder, renal cell carcinoma, and hepatocellular carcinoma. In these cancers, immunotherapy is also becoming a mainstay of treatment regimens and is often combined with other modalities such as surgery, radiation, and chemotherapy.

End-User Insights:

• Hospitals: These act as the more significant hubs where immuno-oncology treatments are administered to patients. They provide a fully comprehensive range of services associated with monoclonal antibodies, checkpoint inhibitors, and ACT delivery. In addition, hospitals will have the infrastructure to manage these therapies' adverse effects and complications to care for cancer patients comprehensively.
• Cancer Research Centers: Such centers are critical in developing and testing new immunotherapies. Most institutions are engaged in active clinical studies concerning the efficacy and safety of new therapies. In these places, patients can access cutting-edge treatments unavailable elsewhere.
• Others: Others include outpatient clinics, privately run specialized cancer treatment centers, and home healthcare providers. These facilities cater to patients who require continued immunotherapy but not necessarily hospitalization. They, therefore, offer convenience and accessibility, especially to those receiving long-term maintenance therapies.

Regional Insights

• North America: North America dominates the largest market share, especially in the US, due to its well-established healthcare infrastructure, acceptance and investment in new technologies, and high funding for R&D. Hence, a high incidence of cancer in the region, coupled with the presence of major pharmaceutical companies, continues to drive growth in immunotherapies.
• Asia Pacific: The region of Asia Pacific is also presenting fast growth in the cancer immunotherapy market, driven by an increase in cancer incidence, improving healthcare infrastructure, and increasing access to newer treatments. Countries such as China, Japan, and India are among the recipients of investments in cancer research, thus expanding the market scope.
• Europe: Europe is another primary market for cancer immunotherapy, with Germany, France, and the UK leading in adopting these treatments. The primary driving forces behind the European market are robust healthcare infrastructure, government support for cancer research funding, and enhanced awareness about the benefits accruable from the use of immunotherapy treatments.
• Latin America: Latin America is an emerging market for cancer immunotherapy. Countries such as Brazil and Mexico are leading this. Though still in the developing stage, the market for immunotherapy in this region is growing due to better healthcare facilities and increased awareness about cancer treatments.
• Middle East and Africa: The Middle East & Africa cancer immunotherapy market is presently nascent but will soon grow due to the increasing cancer cases and rising access to healthcare. Raising awareness in cancer care infrastructure and advancing treatment processes are slowly opening up this market.

Cancer Immunotherapy Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Product Type, Cancer Type, End-User, and Region.

Segmentation:

By Product Type:

• Monoclonal Antibodies
• Immunomodulators
• Checkpoint Inhibitors
• Adoptive Cell Therapy
• Others

By Cancer Type:

• Lung Cancer
• Colorectal Cancer
• Melanoma
• Breast Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By End-User:

• Hospitals
• Cancer Research Centers
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Cancer Immunotherapy Market include Amgen, Inc., AstraZeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily And Company, F. Hoffmann-La Roche, Ltd, Pfizer, Inc., Johnson & Johnson Services, Inc, Merck & Co., Inc, Novartis AG, Immunocore, Ltd.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

• In June 2024, A new phase 2 research started to examine a triple medication combination for pancreatic cancer. The University of Glasgow and the NHS Greater Glasgow and Clyde have initiated a mid-stage trial to test a new drug combination as a first-line treatment for patients with metastatic pancreatic cancer. The phase 2 PRIMUS-006 study, part of the Precision-Panc Platform, will evaluate Eli Lilly and Genentech's Gemzar (gemcitabine) in combination with Merck & Co's Keytruda (pembrolizumab), known as MSD outside the US and Canada, and Immodulon Therapeutics' investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC).
• In April 2024, Hope beckons as the first homegrown cell therapy for cancer treatment is announced. President Droupadi Murmu introduced India's first indigenously developed CAR T-cell therapy for cancer treatment, calling it a " breakthrough" that will give humanity new hope in the fight against the disease. NexCAR19 CAR T-cell therapy is the country's first 'Made in India' cell therapy, and it will considerably reduce cancer treatment costs. This gene-based therapy, developed by the Indian Institute of Technology (IIT) Bombay and the Tata Memorial Centre, aims to cure several types of cancer.

• Amgen, Inc.
• AstraZeneca, PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lily And Company
• F. Hoffmann-La Roche, Ltd
• Pfizer, Inc.
• Johnson & Johnson Services, Inc
• Merck & Co., Inc
• Novartis AG
• Immunocore, Ltd

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Cancer Type
  • Market Snippet, By End-User
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, By Product Type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Monoclonal Antibodies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Immunomodulators
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Adoptive Cell Therapy
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Cancer Type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Lung Cancer
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Colorectal Cancer
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Melanoma
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Breast Cancer
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Head & Neck Cancer
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Prostate Cancer
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By End-User, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Cancer Research Centers
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Cancer Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Amgen, Inc.
• AstraZeneca, PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lily And Company
• F. Hoffmann-La Roche, Ltd
• Pfizer, Inc.
• Johnson & Johnson Services, Inc
• Merck & Co., Inc
• Novartis AG
• Immunocore, Ltd

The Last Word

• Future Impact
• About Us
• Contact